CODA Assembly of Mutant Genes

Information

  • Research Project
  • 6999982
  • ApplicationId
    6999982
  • Core Project Number
    R41AI066758
  • Full Project Number
    1R41AI066758-01
  • Serial Number
    66758
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2005 - 19 years ago
  • Project End Date
    7/31/2006 - 18 years ago
  • Program Officer Name
    BREEN, JOSEPH J.
  • Budget Start Date
    8/1/2005 - 19 years ago
  • Budget End Date
    7/31/2006 - 18 years ago
  • Fiscal Year
    2005
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/22/2005 - 19 years ago
Organizations

CODA Assembly of Mutant Genes

DESCRIPTION (provided by applicant): The opportunity addressed by this proposal is to provide the scientific and medical communities with the ability to perform rapid, inexpensive, and accurate mutation studies of any protein, using a scaffold based on synthetic genes computationally optimized for DNA self assembly and for expression and translation in an in vitro or in vivo system of choice. Current gene synthesis methods are time-consuming and expensive, and are therefore unsuited to rapid and routine large-scale mutation studies of proteins of biomedical interest. However, whether pathogens occur naturally or are engineered by bioterrorists, mutational variation is one of the primary methods by which they escape the immune system. Indeed, deliberately engineering a pathogen mutant to evade the immune response generated by current vaccines has been identified as one strategy by which a bioterrorist could achieve high penetration into the general population. Easy access to large-scale mutational studies would allow those variations that successfully evade the immune system, and hence render current vaccines ineffective, to be identified, studied, and prepared for in advance. Mutational studies are also one of the primary methods by which biomedical researchers carry out protein sequence-structure studies, and RNA splicing variants are a major source of protein diversity in higher eukaryotes. The ready ability to study mutations and splice variants would advance biology and medicine on many fronts, for example, by supporting pharmacogenomics research, or by enabling protein arrays of the major mutants or splice variants of a protein of interest. Because of worldwide bioterrorism threats and emerging diseases, the development of safe, rapid, and inexpensive manufacturing methods for mutational variants of the genes and proteins of Class A, B & C bioterrorism agents for vaccine development, as well as mutant proteins for all types of biomedical research, is a high national priority.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R41
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    582993
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:582993\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    VERDEZYNE, INC.
  • Organization Department
  • Organization DUNS
    193013963
  • Organization City
    CARLSBAD
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    920106601
  • Organization District
    UNITED STATES